Author
Listed:
- Elisa Carrillo
(University of Texas Health Science Center at Houston)
- Alejandra Montaño Romero
(Johns Hopkins University School of Medicine
Johns Hopkins University School of Medicine)
- Cuauhtemoc U. Gonzalez
(University of Texas Health Science Center at Houston
University of Texas Health Science Center at Houston)
- Andreea L. Turcu
(27-31)
- Santiago Vázquez
(27-31)
- Edward C. Twomey
(Johns Hopkins University School of Medicine
Johns Hopkins University School of Medicine
Johns Hopkins University School of Medicine
Diana Helis Henry Medical Research Foundation)
- Vasanthi Jayaraman
(University of Texas Health Science Center at Houston
University of Texas Health Science Center at Houston)
Abstract
Memantine is an US Food and Drug Administration (FDA) approved drug that is thought to selectively inhibit NMDA-subtype of ionotropic glutamate receptors (NMDARs). NMDARs enable calcium influx into neurons and are critical for normal brain function. However, increasing evidence shows that calcium influx in neurological diseases is augmented by calcium-permeable AMPA-subtype ionotropic glutamate receptors (AMPARs). Here, we demonstrate that these calcium-permeable AMPARs (CP-AMPARs) are inhibited by memantine. Electrophysiology unveils that memantine inhibition of CP-AMPARs is dependent on their calcium permeability and the presence of their neuronal auxiliary subunit transmembrane AMPAR regulatory proteins (TARPs). Through cryo-electron microscopy we elucidate that memantine blocks CP-AMPAR ion channels in a unique mechanism of action from NMDARs. Furthermore, we demonstrate that memantine inhibits a gain of function AMPAR mutation found in a patient with a neurodevelopmental disorder. Our findings unlock potential exploitation of this site to design more specific drugs targeting CP-AMPARs.
Suggested Citation
Elisa Carrillo & Alejandra Montaño Romero & Cuauhtemoc U. Gonzalez & Andreea L. Turcu & Santiago Vázquez & Edward C. Twomey & Vasanthi Jayaraman, 2025.
"Memantine inhibits calcium-permeable AMPA receptors,"
Nature Communications, Nature, vol. 16(1), pages 1-9, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60543-5
DOI: 10.1038/s41467-025-60543-5
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60543-5. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.